Compare CNOBP & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNOBP | WGSWW |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 493 | 1300 |
| Industry | Major Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | CNOBP | WGSWW |
|---|---|---|
| Price | $24.41 | $0.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.6K | ★ 106.4K |
| Earning Date | N/A | 02-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $305,450,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 50.79 |
| 52 Week Low | $20.75 | $0.00 |
| 52 Week High | $24.85 | $0.23 |
| Indicator | CNOBP | WGSWW |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 42.82 |
| Support Level | $24.42 | $0.01 |
| Resistance Level | $24.84 | $0.02 |
| Average True Range (ATR) | 0.16 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 70.83 | 29.75 |
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.